Gavreto - direct healthcare professional communication (DHPC)

pralsetinib
DHPCHuman

Estonian is available via eTranslation, the European Commission's machine translation service.

Translate to Estonian | Important information about machine translation

Programmist

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Dokumendid

Direct healthcare professional communication (DHPC): Gavreto (pralsetinib): Increased risk for tuberculosis and measures to minimise this risk

English (EN) (206.81 KB - PDF)

Esmakordselt avaldatud:
Vaata

Key facts

Medicine name
Gavreto
Active substance
pralsetinib
Therapeutic area (MeSH)
Carcinoma, Non-Small-Cell Lung
Procedure number
EMEA/H/C/005413
Regulatory outcome
Variation
DHPC type
  • Adverse event
  • Post-authorisation measure
Human ATC codes
L01XE
Dissemination date

Share this page